| 翻訳と辞書 |
| Nucleofection ： ウィキペディア英語版 |
Nucleofection
Nucleofection is an electroporation-based transfection method which enables transfer of nucleic acids such as DNA and RNA into cells by applying a specific voltage and reagents. Nucleofection, also referred to as Nucleofector Technology, was invented by the biotechnology company Amaxa. “Nucleofector” and “nucleofection” are trademarks owned by Lonza Cologne AG, part of the Lonza Group.
== Applications ==
Nucleofection is a method to transfer substrates into mammalian cells so far considered difficult or even impossible to transfect. Examples for such substrates are nucleic acids, like the DNA of an isolated gene cloned into a plasmid, or small interfering RNA (siRNA) for knocking down expression of a specific endogenous gene.
Primary cells, for example stem cells, especially fall into this category, although many other cell lines are also difficult to transfect. Primary cells are freshly isolated from body tissue and thus cells are unchanged, closely resembling the in-vivo situation, and are therefore of particular relevance for medical research purposes. In contrast, cell lines have often been cultured for decades and may significantly differ from their origin.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Nucleofection」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|